Traded Nov 13 – Nov 16, 2026 · largest single transaction ~$754K
Show all 2 transactions
Nov 13, 2026~$754K · 99K sh @ $7.63
DetailsOfficial recordNov 16, 2026~$750K · 101K sh @ $7.42
DetailsOfficial record
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
KURA · NASDAQ · Pharmaceutical Preparations
Kura Oncology (KURA) · oqro.io/stocks/KURA · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$7.09−0.68 (−8.75%)
Close of Nov 16, 2026, vs Nov 13 · end-of-day, not a live quote
2 routine filings (option exercises, shares withheld for taxes, grants, gifts) are not listed here. Show them
Traded Nov 13 – Nov 16, 2026 · largest single transaction ~$754K
Nov 13, 2026~$754K · 99K sh @ $7.63
DetailsOfficial recordNov 16, 2026~$750K · 101K sh @ $7.42
DetailsOfficial recordInsider selling
Traded Nov 16 · filed the same day
A Kura Oncology officer told the SEC about a plan to sell $148K of Kura Oncology shares around Nov 16, 2026. The shares were not acquired as compensation. That is a tiny part of all Kura Oncology shares.
Insider selling
Traded Nov 16 · filed the same day
A Kura Oncology officer told the SEC about a plan to sell $67K of Kura Oncology shares around Nov 16, 2026. The shares were not acquired as compensation.
Insider selling
Traded Nov 16 · filed the same day
A Kura Oncology officer told the SEC about a plan to sell $55K of Kura Oncology shares around Nov 16, 2026. The shares were not acquired as compensation.
Insider selling
Traded Nov 16 · filed the same day
A Kura Oncology officer told the SEC about a plan to sell $36K of Kura Oncology shares around Nov 16, 2026. The shares were not acquired as compensation.
Brian T. Powl (Officer) plans to sell ~$71K of Kura Oncology
Planned, from payMollie Leoni (Chief Medical Officer) sold ~$310K of Kura Oncology
Planned saleBrian T. Powl (Chief Commercial Officer) sold ~$166K of Kura Oncology
Planned saleMollie Leoni (Chief Medical Officer) sold ~$131K of Kura Oncology
Automatic saleBrian T. Powl (Chief Commercial Officer) sold ~$95K of Kura Oncology
Automatic saleTeresa Brophy Bair (Chief Legal Officer) sold ~$89K of Kura Oncology
Automatic saleBrian T. Powl (Chief Commercial Officer) sold ~$84K of Kura Oncology
Planned saleKathleen Ford (Chief Operating Officer) sold ~$72K of Kura Oncology
Automatic saleThomas James Doyle (SVP, Finance & Accounting) sold ~$48K of Kura Oncology
Automatic saleKathleen Ford (Chief Operating Officer) sold ~$39K of Kura Oncology
Planned saleInsider selling
Traded Sep 24 · filed 1 day laterNot reported under a pre-arranged trading plan
Since the trade −34.7% · S&P 500 −3.5% · to Nov 16
Kura Oncology's Chief Scientific Officer sold $225K of Kura Oncology shares. The filing does not indicate a pre-arranged trading plan.
Troy Edward Wilson (President and CEO) sold ~$327K of Kura Oncology
Automatic saleMollie Leoni (Chief Medical Officer) sold ~$110K of Kura Oncology
Automatic saleTeresa Brophy Bair (Chief Legal Officer) sold ~$79K of Kura Oncology
Automatic saleBrian T. Powl (Chief Commercial Officer) sold ~$80K of Kura Oncology
Automatic saleKathleen Ford (Chief Operating Officer) sold ~$62K of Kura Oncology
Automatic saleThomas James Doyle (SVP, Finance & Accounting) sold ~$41K of Kura Oncology
Automatic saleInsider buying
Traded Sep 8, 2025 · filed 1 day later
Since the trade −12.9% · S&P 500 +14.0% · to Nov 16
The CEO of Kura Oncology paid $410K out of pocket for Kura Oncology shares. Shares held went up 98% with this purchase.
Insider buying
Traded Aug 13, 2025 · filed 1 day later
Since the trade +9.2% · S&P 500 +14.7% · to Nov 16
The CEO of Kura Oncology paid $90K out of pocket for Kura Oncology shares. Shares held went up 36% with this purchase.
Kathleen Ford (Chief Operating Officer) sold ~$9.8K of Kura Oncology
Planned saleTeresa Brophy Bair (Chief Legal Officer) sold ~$9.3K of Kura Oncology
Planned saleFaheem Hasnain (Director) sold ~$181K of Kura Oncology
Planned saleTeresa Brophy Bair (Chief Legal Officer) sold ~$38K of Kura Oncology
Automatic saleTeresa Brophy Bair (Chief Legal Officer) sold ~$19K of Kura Oncology
Automatic saleThomas James Doyle (SVP, Finance & Accounting) sold ~$18K of Kura Oncology
Automatic saleMollie Leoni (Chief Medical Officer) sold ~$18K of Kura Oncology
Automatic saleKathleen Ford (Chief Operating Officer) sold ~$14K of Kura Oncology
Automatic saleBrian T. Powl (Chief Commercial Officer) sold ~$12K of Kura Oncology
Automatic saleMollie Leoni (Chief Medical Officer) sold ~$11K of Kura Oncology
Automatic saleFrancis Burrows (Chief Scientific Officer) sold ~$10K of Kura Oncology
Automatic saleThomas James Doyle (SVP, Finance & Accounting) sold ~$8.8K of Kura Oncology
Automatic saleFrancis Burrows (Chief Scientific Officer) sold ~$6.7K of Kura Oncology
Automatic saleMollie Leoni (Chief Medical Officer) sold ~$6.4K of Kura Oncology
Automatic saleMollie Leoni (Chief Medical Officer) sold ~$4.3K of Kura Oncology
Automatic sale2 open-market purchases and 10 open-market sales by insiders of KURA between Feb 3, 2026 and today, placed against the company's last 4 earnings releases. The latest on file was filed Nov 10, 2026. The data provider lists the next release for Mar 3, 2027; that date may change.
PurchaseSale30 days before a release30 days after
| Earnings release | 30 days before | On the day | 30 days after |
|---|---|---|---|
| Nov 10, 2026 | None | None | 2 purchases |
| Aug 12, 2026 | None | None | None |
| May 12, 2026 | None | None | None |
| Mar 5, 2026 | None | None | None |
Companies set trading windows, which usually close shortly before results and reopen after them, and insiders may trade under 10b5-1 plans adopted months earlier. A date alone does not show what a person knew or why they traded. Past release dates are the dates the company filed its 8-K with Item 2.02. An upcoming date, when one is mentioned, comes from the data provider's earnings calendar (Finnhub): it is not a company filing, it is not estimated by OQRO, and it may change. Open-market purchases and sales as reported on Form 4. Largest purchases around earnings, all companies